Search research articles
Contact Us
Filters
Showing results (531-540 of 573) with videos related to
Page
of 58
Sort By:
Clinical and Translational Science
|
October 20, 2021
Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial
Susanne H Hodgson, Poppy Iveson, Jessica Larwood, et al.
Clinical Colorectal Cancer
|
October 26, 2021
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors
Chara Stavraka, Athanasios Pouptsis, Alicja Synowiec, et al.
The Journal of Pathology. Clinical Research
|
May 14, 2020
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer
Antonia K Roseweir, James H Park, Sanne Ten Hoorn, et al.
The Lancet. Oncology
|
April 2, 2021
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
Timothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, et al.
Science Advances
|
August 13, 2025
Classic Maya response to multiyear seasonal droughts in Northwest Yucatán, Mexico
Daniel H James, Stacy A Carolin, Sebastian F M Breitenbach, et al.
The Lancet. Oncology
|
July 1, 2021
Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply
Angela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
Elisa Fontana, Jeff Meyers, Alberto Sobrero, et al.
ESMO Open
|
June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial
A Lamarca, D H Palmer, H S Wasan, et al.
The New England Journal of Medicine
|
March 29, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto F Sobrero, Anthony F Shields, et al.
Page
of 58
Search research articles
Search
Showing results (531-540 of 573) with videos related to
Sort By:
Page
of 58
Clinical and Translational Science
|
October 20, 2021
Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial
Susanne H Hodgson, Poppy Iveson, Jessica Larwood, et al.
Clinical Colorectal Cancer
|
October 26, 2021
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors
Chara Stavraka, Athanasios Pouptsis, Alicja Synowiec, et al.
The Journal of Pathology. Clinical Research
|
May 14, 2020
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer
Antonia K Roseweir, James H Park, Sanne Ten Hoorn, et al.
The Lancet. Oncology
|
April 2, 2021
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
Timothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, et al.
Science Advances
|
August 13, 2025
Classic Maya response to multiyear seasonal droughts in Northwest Yucatán, Mexico
Daniel H James, Stacy A Carolin, Sebastian F M Breitenbach, et al.
The Lancet. Oncology
|
July 1, 2021
Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply
Angela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
Elisa Fontana, Jeff Meyers, Alberto Sobrero, et al.
ESMO Open
|
June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial
A Lamarca, D H Palmer, H S Wasan, et al.
The New England Journal of Medicine
|
March 29, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto F Sobrero, Anthony F Shields, et al.
Page
of 58